Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kite Pharma
Pharma
Daiichi, Fosun, Yuhan and more—Fierce Pharma Asia
AZ and Daiichi's Dato-DXd hit a setback. Fosun will buy Kite out of their China joint venture. Yuhan and J&J ended an EGFR partnership. And more.
Angus Liu
Sep 27, 2024 10:15am
Gilead's Kite exits China cell therapy JV with Fosun Pharma
Sep 19, 2024 4:23pm
Kite will evaluate Cellares' cell therapy manufacturing platform
Jun 27, 2024 8:00am
Cytiva rolls out new CAR-T manufacturing platform
May 30, 2024 9:19am
Gilead's Kite shortens Yescarta manufacturing time with FDA nod
Jan 30, 2024 8:39am
FDA wants classwide boxed warning on existing CAR-Ts
Jan 23, 2024 3:27am
